Repligen Corporation

NASDAQ:RGEN

Medical - Instruments & Supplies

Healthcare
$172.67 -2.74%

-$3.66 today

Market cap
$11.04B
Beta
1.08
P/E (TTM)
142.4
EPS (TTM)
$0.91
52W Low $100.99High $175.77

Volume 1.30M

Average 1.08M

RGEN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Repligen CorporationNASDAQ: RGEN

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $23.77M fell 4.0% year over year, ahead of the -7.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.1% from the prior quarter. Over 3 fiscal years it compounded at +19.4% a year.

Context

  • Depreciation & amortization amounted to 13.1% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -4.0% holds above the trailing-twelve-month pace of -7.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$23.77M-3.1% QoQ
Last fiscal yearDec 2025
$96.96M+12.0% YoY
LTMJun 2026
$97.31M-7.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.0%——
1 year+12.0%——
3-year CAGR+19.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
96.96M USD
Year-over-year change
+12.0%
4-year CAGR
+26.0%

Depreciation & Amortization vs competitors

How RGEN compares with its peers on the latest reported figures

  • RGEN's LTM Jun 2026 depreciation & amortization of $97.31M is the 6th largest of the 9 companies compared; the peer median is $164.86M.
  • Its year-over-year change of -7.0% is the 6th highest of 9, against a peer median of -4.2%.
  • Depreciation & amortization amounts to 12.4% of revenue for RGEN, versus a peer median of 6.5%.
RGEN Competitors Peer median
Depreciation & Amortization for RGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$3.11B +11.2%-6.3%6.6%
AVTRAvantor, Inc.LTM Jun 2026$418.4M +3.1%+0.4%6.4%
AAgilent Technologies, Inc.LTM Jul 2026$271M -5.2%-3.1%3.7%
QGENQiagen N.V.LTM Jun 2026$202.13M +7.0%-2.4%9.6%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$127.6M -23.5%+6.4%4.9%
RGENRepligen CorporationLTM Jun 2026$97.31M -7.0%+19.4%12.4%
TECHBio-Techne CorporationLTM Sep 2026$96.75M -8.8%-3.2%7.9%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$56.96M -3.2%+16.6%27.3%
BLFSBioLife Solutions, Inc.LTM Mar 2026$4M -48.5%-34.2%4.0%
Peer median (excluding RGEN) $164.86M-4.2%-2.8%6.5%

Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income128.29M185.96M41.58M(25.51M)48.89M
Depreciation & Amortization38.45M57.01M86.11M86.56M96.96M
Deferred Income Tax6.52M(1.35M)2.32M(16.79M)(3.37M)
Stock-Based Compensation27.5M27.32M25.58M48.07M32.61M
Change in Working Capital(102.13M)(69.84M)(8.64M)60.92M(50.88M)
Accounts Receivables(46.53M)(3.6M)(3.31M)(14.03M)(17.17M)
Inventory(89.78M)(57.2M)40.97M56.9M(14.95M)
Accounts Payables19.52M(8.2M)(9.8M)12.9M(4.15M)
Other Working Capital14.66M(841K)(36.5M)5.16M(14.62M)
Other Non-Cash Items20.39M(27.01M)(33.03M)22.15M(6.79M)
Operating Cash Flow119.02M172.08M113.92M175.39M117.42M
Capital Expenditures(67.09M)(133.35M)(38.99M)(32.91M)(23.52M)
Acquisitions (Net)(149.89M)0(186.64M)(54.77M)(70.33M)
Purchases of Investments0(100M)00(200.26M)
Sales of Investments00102.32M00
Other Investing Activities(4.19M)(48.4M)(2.73M)(5.94M)(4.37M)
Investing Cash Flow(221.17M)(233.24M)(123.28M)(86.38M)(298.47M)
Debt Repayment(21K)0290.09M(69.94M)0
Common Stock Issued3.88M3.71M1.08M4.29M3.18M
Common Stock Repurchased00(14.39M)00
Dividends Paid00000
Other Financing Activities(2.9M)(17.04M)(27.82M)(17.26M)(18.38M)
Financing Cash Flow961K(13.34M)248.96M(82.9M)(15.21M)
Effect of Forex Changes(12.29M)(5.87M)(11.74M)(77K)4.93M
Net Change in Cash(113.48M)(80.36M)227.87M6.03M(191.33M)
Free Cash Flow51.93M38.74M74.93M142.49M93.9M

Repligen Corporation

NASDAQ:RGEN

Intrinsic Alpha fair value

Locked

Current Price

$172.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.